Medical device company Zimmer Biomet (NYSE:ZBH) will be reporting earnings tomorrow before market hours. Here’s what investors should know. Zimmer Biomet beat analysts’ revenue expectations by ...

Zimmer Biomet CPT ® Hip System implants may put patients at an increased risk of suffering a broken thigh bone near the device. In some cases, patients may even need to undergo corrective surgery. At ...

Expected to Enhance Zimmer Biomet's Financial Profile; Immediately Accretive to Revenue Growth and Accretive to Adjusted EPS within 24 Months of Deal Close WARSAW, Ind. and ENGLEWOOD, Colo., ...

Zimmer Biomet posted fourth-quarter revenue growth of 5% in constant currency, which is generally consistent with the preceding quarters in 2024. Why it matters: As Zimmer Biomet has pursued a ...

Zimmer Biomet posted Q4 adjusted EPS of $2.31, surpassing estimates, with sales of $2.02B, driven by strong knee and hip product growth. The company expects FY25 adjusted EPS of $8.15-$8.35 ...

Zimmer Biomet recently announced entering a definitive agreement to acquire all outstanding common shares of Paragon 28. Under the agreement, Zimmer Biomet will pay $13.00 per share, valuing ...

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Zimmer Biomet Holdings (ZBH – Research Report), with a price target of $122.00. The company’s shares opened ...

Zimmer Biomet (NYSE: ZBH) + shares dipped slightly today on fourth-quarter results that came in just ahead of the consensus forecast on Wall Street. Shares of ZBH fell 1.6% to $106.50 apiece in ...